Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA.
Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi 39762, USA.
J Vet Intern Med. 2023 Mar;37(2):528-536. doi: 10.1111/jvim.16652. Epub 2023 Feb 21.
Evidence supporting the effectiveness of therapeutic protocols for nonassociative immune-mediated hemolytic anemia (na-IMHA) is weak.
HYPOTHESIS/OBJECTIVES: Investigate the efficacy of various drugs in na-IMHA.
Two hundred forty-two dogs.
Multi-institutional retrospective study (2015-2020). Immunosuppressive effectiveness was determined by time to packed cell volume (PCV) stabilization and duration of hospitalization through analysis by mixed model linear regression. Occurrence of disease relapse, death, and antithrombotic effectiveness, were analyzed using mixed model logistic regression.
Use of corticosteroids vs a multi-agent protocol had no effect on time to PCV stabilization (P = .55), duration of hospitalization (P = .13), or case fatality (P = .06). A higher rate of relapse (P = .04; odds ratio: 3.97; 95% confidence interval [CI]: 1.06-14.8) was detected in dogs receiving corticosteroids (11.3%) during follow-up (median: 28.5 days, range: 0-1631 days) compared to multiple agents (3.1%) during follow up (median: 47.0 days, range: 0-1992 days). When comparing drug protocols, there was no effect on time to PCV stabilization (P = .31), relapse (P = .44), or case fatality (P = .08). Duration of hospitalization was longer, by 1.8 days (95% CI: 0.39-3.28 days), for the corticosteroid with mycophenolate mofetil group (P = .01) compared to corticosteroids alone. Use of clopidogrel vs multiple agents had no effect on development of thromboses (P ≥ .36).
Addition of a second immunosuppressive agent did not alter immediate outcome measures but might be associated with a reduction in relapse. Use of multiple antithrombotic agents did not reduce incidence of thrombosis.
支持非关联免疫介导性溶血性贫血(na-IMHA)治疗方案有效性的证据很薄弱。
假设/目的:研究各种药物在 na-IMHA 中的疗效。
242 只狗。
多机构回顾性研究(2015-2020 年)。通过混合模型线性回归分析,用红细胞压积(PCV)稳定时间和住院时间来确定免疫抑制的效果。使用混合模型逻辑回归分析疾病复发、死亡和抗血栓形成的效果。
与多药物方案相比,使用皮质类固醇对 PCV 稳定时间(P = 0.55)、住院时间(P = 0.13)或病死率(P = 0.06)均无影响。在接受皮质类固醇治疗的狗(11.3%)中,在随访期间(中位数:28.5 天,范围:0-1631 天),复发率(P = 0.04;优势比:3.97;95%置信区间[CI]:1.06-14.8)高于接受多药物治疗的狗(3.1%)(中位数:47.0 天,范围:0-1992 天)。比较药物方案时,对 PCV 稳定时间(P = 0.31)、复发(P = 0.44)或病死率(P = 0.08)均无影响。皮质类固醇联合吗替麦考酚酯组的住院时间延长 1.8 天(95%CI:0.39-3.28 天),与单独使用皮质类固醇相比(P = 0.01)。与多药物方案相比,使用氯吡格雷对血栓形成的发展无影响(P≥0.36)。
添加第二种免疫抑制剂不会改变即刻的预后指标,但可能与降低复发率有关。使用多种抗血栓药物并不能降低血栓形成的发生率。